Neem Leaf Glycoprotein Modulation of Tumor Immunity

Neem Leaf Glycoprotein (NLGP) is a naturally derived immunomodulator isolated from the leaves of Azadirachta indica. Robust preclinical studies have shown that NLGP engages antigen‐presenting cells, notably dendritic cells, to instigate a type‐1 polarised immune response. This shift is characterised by enhanced production of interferon‐γ and interleukin‐12, coupled with suppression of interleukin‐10, thereby promoting cytotoxic CD8+ T-cell activation and proliferation. NLGP has demonstrated efficacy across multiple murine tumour models, where it restrains primary tumour growth, inhibits colonisation in metastatic sites and delays progression in chemically induced carcinogenesis. Mechanistic investigations reveal binding of β-glucan motifs within NLGP to C-type lectin receptors on dendritic cells, triggering downstream CARD9–Bcl10–MALT1 assembly and canonical NFκB-driven transcriptional programmes. These events culminate in vascular normalisation, improved T-cell infiltration, reversal of myeloid‐derived suppressor cell activity and restoration of effector functions within the tumour microenvironment. Collectively, these findings position NLGP as a promising next-generation adjuvant immunotherapeutic agent with potential for clinical translation.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Neem Leaf Glycoprotein Modulation of Tumor Immunity publication trend

The graph below shows the total number of articles in neem leaf glycoprotein modulation of tumor immunity across all publications each year (not limited to Nature Index journals).

Technical terms

Antigen-presenting cell: A leukocyte, such as a dendritic cell, that processes and displays antigens to T cells to initiate adaptive immunity.

CARD9–Bcl10–MALT1 complex: A cytosolic assembly triggered by C-type lectin receptor signalling that activates the canonical NFκB pathway.

Type-1 immunity: An immune response dominated by interferon-γ production and cell-mediated cytotoxicity against intracellular pathogens and tumour cells.

β-Glucan: A polysaccharide motif recognized by pattern recognition receptors, critical for lectin-mediated immune activation.

Tumour microenvironment: The cellular milieu surrounding a tumour, including immune cells, stromal elements and vascular networks that influence tumour progression and therapy response.

References

1. Neem leaf glycoprotein binding to Dectin-1 receptors on dendritic cell induces type-1 immunity through CARD9 mediated intracellular signal to NFκB. Cell Communication and Signaling (2024).
2. The immunomodulatory impact of naturally derived neem leaf glycoprotein on the initiation progression model of 4NQO induced murine oral carcinogenesis: a preclinical study. Frontiers in Immunology (2024).
3. NLGP Attenuates Murine Melanoma and Carcinoma Metastasis by Modulating Cytotoxic CD8+ T Cells. Frontiers in Oncology (2020).
4. Neem leaf glycoprotein prevents post-surgical sarcoma recurrence in Swiss mice by differentially regulating cytotoxic T and myeloid-derived suppressor cells. PLOS ONE (2017).
5. Normalization of Tumor Microenvironment by Neem Leaf Glycoprotein Potentiates Effector T Cell Functions and Therapeutically Intervenes in the Growth of Mouse Sarcoma. PLOS ONE (2013).